ATRX and pancreatic endocrine carcinoma: Additional immunohistochemical markers, such as Rb lost and p53 mutant pattern in pancreatic NECs compared with loss of ATRX, DAXX, and menin in panNETs, can help in separating these two entities [8, 9] (III, B).